Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paola Perini

Showing results (11-20 of 101) with videos related to

Pageof 11
Sort By:
Journal of Neurology|April 13, 2006
Mitoxantrone versus cyclophosphamide in secondary-progressive multiple sclerosis: a comparative studyPaola Perini, Massimiliano Calabrese, Michela Tiberio, et al.
Journal of Neuroimmunology|February 21, 2004
The MBP-reactive repertoire is shaped by recognition of minor histocompatibility antigensAntonella Facchinetti, Paolo Gallo, Paola Perini, et al.
Multiple Sclerosis and Related Disorders|September 19, 2018
Herpes simplex virus encephalitis temporally associated with dimethyl fumarate-induced lymphopenia in a multiple sclerosis patientPaola Perini, Francesca Rinaldi, Marco Puthenparampil, et al.
Annals of Neurology|February 1, 2011
No evidence of chronic cerebrospinal venous insufficiency at multiple sclerosis onsetClaudio Baracchini, Paola Perini, Massimiliano Calabrese, et al.
Therapeutic Advances in Neurological Disorders|February 6, 2018
Decreased platelet number in multiple sclerosis during alemtuzumab infusion: a common, transient and clinically silent phenomenonMarco Puthenparampil, Francesca Rinaldi, Lisa Federle, et al.
Frontiers in Psychology|February 9, 2019
D-KEFS ST Failure Identifies Multiple Sclerosis Patients With Worse Objective and Self-Perceived Physical and Cognitive DisabilityAlice Riccardi, Marco Puthenparampil, Francesca Rinaldi, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|September 27, 2019
Alemtuzumab following natalizumab in highly active paediatric-onset multiple sclerosisMonica Margoni, Francesca Rinaldi, Silvia Miante, et al.
Journal of Neurology|September 29, 2019
No evidence of disease activity including cognition (NEDA-3 plus) in naïve pediatric multiple sclerosis patients treated with natalizumabMonica Margoni, Francesca Rinaldi, Alice Riccardi, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|December 21, 2017
Evidence of B-cell dysregulation in severe CNS inflammation after alemtuzumab therapyFrancesca Rinaldi, Lisa Federle, Marco Puthenparampil, et al.
Multiple Sclerosis International|March 25, 2015
Disease-modifying drugs reduce cortical lesion accumulation and atrophy progression in relapsing-remitting multiple sclerosis: results from a 48-month extension studyFrancesca Rinaldi, Paola Perini, Matteo Atzori, et al.
Pageof 11

Showing results (11-20 of 101) with videos related to

Sort By:
Pageof 11
Journal of Neurology|April 13, 2006
Mitoxantrone versus cyclophosphamide in secondary-progressive multiple sclerosis: a comparative studyPaola Perini, Massimiliano Calabrese, Michela Tiberio, et al.
Journal of Neuroimmunology|February 21, 2004
The MBP-reactive repertoire is shaped by recognition of minor histocompatibility antigensAntonella Facchinetti, Paolo Gallo, Paola Perini, et al.
Multiple Sclerosis and Related Disorders|September 19, 2018
Herpes simplex virus encephalitis temporally associated with dimethyl fumarate-induced lymphopenia in a multiple sclerosis patientPaola Perini, Francesca Rinaldi, Marco Puthenparampil, et al.
Annals of Neurology|February 1, 2011
No evidence of chronic cerebrospinal venous insufficiency at multiple sclerosis onsetClaudio Baracchini, Paola Perini, Massimiliano Calabrese, et al.
Therapeutic Advances in Neurological Disorders|February 6, 2018
Decreased platelet number in multiple sclerosis during alemtuzumab infusion: a common, transient and clinically silent phenomenonMarco Puthenparampil, Francesca Rinaldi, Lisa Federle, et al.
Frontiers in Psychology|February 9, 2019
D-KEFS ST Failure Identifies Multiple Sclerosis Patients With Worse Objective and Self-Perceived Physical and Cognitive DisabilityAlice Riccardi, Marco Puthenparampil, Francesca Rinaldi, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|September 27, 2019
Alemtuzumab following natalizumab in highly active paediatric-onset multiple sclerosisMonica Margoni, Francesca Rinaldi, Silvia Miante, et al.
Journal of Neurology|September 29, 2019
No evidence of disease activity including cognition (NEDA-3 plus) in naïve pediatric multiple sclerosis patients treated with natalizumabMonica Margoni, Francesca Rinaldi, Alice Riccardi, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|December 21, 2017
Evidence of B-cell dysregulation in severe CNS inflammation after alemtuzumab therapyFrancesca Rinaldi, Lisa Federle, Marco Puthenparampil, et al.
Multiple Sclerosis International|March 25, 2015
Disease-modifying drugs reduce cortical lesion accumulation and atrophy progression in relapsing-remitting multiple sclerosis: results from a 48-month extension studyFrancesca Rinaldi, Paola Perini, Matteo Atzori, et al.
Pageof 11